» Articles » PMID: 1254701

Ethylenimine-inactivated Rabies Vaccine of Tissue Culture Origin

Overview
Specialty Microbiology
Date 1976 Jan 1
PMID 1254701
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The replication of seven rabies virus strains (CVS, HEP, PV, ERA, WIRAB, CPZ and BOLIVAR) in BHK cells and the inactivation dynamics of these strains by beta-propiolactone, acetylethylenimine, and ethylenimine were studied to find the most immunogenic strain and the most economic and stable inactivating agent for the production of an inactivated tissue culture rabies vaccine for animal use. The seven strains reached the peak of virus production 3 to 5 days after inoculation of the cell culture; PV yielded the highest virus titer (10(9) plaque-forming units/ml). The infectivity of virus suspensions containing 10(7) to 10(8) plaque-forming units/0.1 ml was inactivated by beta-propiolactone in 0.5 h, acetylethylenimine in 3.0 h, and ethylenimine in 1.0 h. Most of the vaccine lots prepared with the different strains and inactivating agents passed a modified National Institutes of Health potency test. The vaccines prepared with the PV strain had consistently higher antigenic values (equal or better than four) than the other six strains. This difference was highly significant (F6,12=59.8), whereas there were no statistically significant differences among the antigenic values of the vaccine lots prepared with the three inactivating agents. Batches of lyophilized and liquid vaccine stored at 4 C maintained potency for over 1 year. Ten dogs vaccinated with a vaccine prepared with the PV strain and inactivated with ethylenimine developed a good antibody response and resisted challenge 60 days after vaccination, while seven of eight nonvaccinated controls died of rabies. This information indicates that an inactivated, stable, economic, and easy-to-prepare rabies vaccine can be produced in BHK cells by using the PV strain and ethylenimine as an inactivating agent.

Citing Articles

Infection and Prevention of Rabies Viruses.

Chen S, Rai C, Wang S, Chen Y Microorganisms. 2025; 13(2).

PMID: 40005749 PMC: 11858514. DOI: 10.3390/microorganisms13020380.


Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: Study.

Olayan E, El-Khadragy M, Mohamed A, Mohamed A, Shebl R, Yehia H Biomed Res Int. 2019; 2019:4518163.

PMID: 31008105 PMC: 6441502. DOI: 10.1155/2019/4518163.


Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus.

Yuan L, Kang S, Ward L, To T, Saif L J Virol. 1998; 72(1):330-8.

PMID: 9420231 PMC: 109380. DOI: 10.1128/JVI.72.1.330-338.1998.


Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production.

Larghi O, Nebel A J Clin Microbiol. 1980; 11(2):120-2.

PMID: 7358836 PMC: 273335. DOI: 10.1128/jcm.11.2.120-122.1980.


Production and partial characterization of monoclonal antibodies to four Chlamydia psittaci isolates.

ANDERSEN A, Van Deusen R Infect Immun. 1988; 56(8):2075-9.

PMID: 3294184 PMC: 259525. DOI: 10.1128/iai.56.8.2075-2079.1988.

References
1.
Stoker M, Macpherson I . SYRIAN HAMSTER FIBROBLAST CELL LINE BHK21 AND ITS DERIVATIVES. Nature. 1964; 203:1355-7. DOI: 10.1038/2031355a0. View

2.
WIKTOR T, Fernandes M, KOPROWSKI H . CULTIVATION OF RABIES VIRUS IN HUMAN DIPLOID CELL STRAIN WI-38. J Immunol. 1964; 93:353-66. View

3.
KOPROWSKI H, Black J . Studies on chick embryo adapted rabies virus. III. Duration of immunity in vaccinated dogs. Proc Soc Exp Biol Med. 1952; 80(3):410-5. DOI: 10.3181/00379727-80-19640. View

4.
Abelseth M . An Attenuated Rabies Vaccine for Domestic Animals Produced in Tissue Culture. Can Vet J. 1964; 5(11):279-86. PMC: 1695899. View

5.
Larghi O, Nebel A, Lazaro L, Savy V . Sensitivity of bhk-21 cells supplemented with diethylaminoethyl-dextran for detection of street rabies virus in saliva samples. J Clin Microbiol. 1975; 1(3):243-5. PMC: 275044. DOI: 10.1128/jcm.1.3.243-245.1975. View